Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of Depigoid Phleum in allergic rhinitis/rhinoconjunctivitis
2010-018562-23Phase 2Terminated
- Sponsor
- LETI Pharma
- Start
- May 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of depigoid phleum in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and asthma (4 arms), sponsored by LETI Pharma. Primary endpoint: Change in conjunctival provocation test response threshold. Started May 2010; status: terminated.
02
Drugs
depigoid phleum
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2010-018562-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018562-23.